Anamorelin
Anamorelin is a GHRP by mechanism but not by structure — an orally active, non-peptide ghrelin-receptor agonist studied almost entirely in the context of cancer-related appetite loss, not general GH-axis research.
Not available from KYIN Peptides in any form — provided here as a research reference only.
What Is Anamorelin?
Anamorelin is a small-molecule agonist of the ghrelin receptor (GHSR1a) — the same receptor targeted by peptide GHRPs such as Ipamorelin and Hexarelin. Unlike those compounds, anamorelin is not a peptide at all: it's a synthetic small molecule, which is also why it's orally bioavailable rather than requiring injection. It was developed by the Swiss pharmaceutical company Helsinn Group in partnership with Japan's Ono Pharmaceutical.
Research Focus
Unlike most compounds in this category, anamorelin's research base is concentrated almost entirely on one indication: cancer anorexia-cachexia syndrome, the appetite loss and involuntary weight/muscle loss that frequently accompanies advanced cancer, studied most extensively in non-small-cell lung cancer (NSCLC) patients. See our GHRH & Growth Hormone research overview for how it fits alongside the peptide GHRPs and GHRH analogs KYIN stocks, and our GHRH vs GHRP comparison for the receptor-level distinction between the two mechanism classes.
Clinical & Preclinical Trial Data
Anamorelin's Phase 3 program (the ROMANA 1 and ROMANA 2 trials, plus a ROMANA 3 safety extension) enrolled advanced NSCLC patients with cachexia and found that anamorelin produced significant increases in body weight and lean body mass compared to placebo. However, the trials did not show a matching improvement in handgrip strength, a co-primary endpoint regulators weighed heavily — a key reason the compound has not been approved in the United States. In Japan, Ono Pharmaceutical's own trial data supported approval in 2021 under the brand name Adlumiz, for cachexia associated with non-small-cell lung cancer, gastric cancer, pancreatic cancer, and colorectal cancer — the world's first approval of a ghrelin-receptor agonist for cancer cachexia.
Availability
Anamorelin is not available from KYIN Peptides in any form, including by special order. This page is provided as a research reference only, alongside the peptide GHRPs and GHRH analogs we do stock.
Anamorelin questions
What is Anamorelin?
Anamorelin is an orally active, small-molecule ghrelin-receptor (GHSR1a) agonist — a GHRP by mechanism, even though it is not itself a peptide. It was developed by Helsinn Group in partnership with Ono Pharmaceutical, primarily studied for cancer-related appetite loss and cachexia.
Is Anamorelin a peptide?
No. Anamorelin is a small, non-peptide molecule. It shares its mechanism of action — ghrelin-receptor (GHSR1a) agonism — with peptide GHRPs like Ipamorelin and Hexarelin, but is structurally unrelated to them and, unlike most peptides, is orally bioavailable.
Is Anamorelin FDA-approved?
Not in the United States. Anamorelin has not received FDA approval for cancer anorexia-cachexia syndrome. It is approved in Japan, where Ono Pharmaceutical markets it as Adlumiz for cachexia associated with non-small-cell lung cancer, gastric cancer, pancreatic cancer, and colorectal cancer.
Does KYIN Peptides sell Anamorelin?
No. Anamorelin is not available from KYIN Peptides in any form, including by special order. This page is provided as a research reference only.
Researching the GH Axis?
Anamorelin isn't available from KYIN, but explore the GHRH analogs and GHRPs we do stock.